ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

Coagulation Conundrums: Managing Hemostatic and Thrombotic Complications in Young Women

In a case-based discussion as part of this year’s Education Program, Andra James, MD, MPH, and Margaret Ragni, MD, MPH, will answer challenging questions...

ASH-a-Palooza Redux

The 2018 ASH Annual Meeting in San Diego marked the debut of ASH-a-Palooza, the reimagined Trainee Day. This new educational experience offers a relaxed,...

DOACs: From Clinical Trials to Real-World Clinical Encounters

In the last decade, five direct oral anticoagulants (DOACs) have made their way to the clinic, but clinicians may encounter challenging patient scenarios for...

200 Years of Hodgkin Lymphoma

This year’s ASH Education Program features a look at the progress that has been made in the two centuries since Thomas Hodgkin entered medicine....

Education Program Preview

Interview with Education Program Co-Chairs Elisabeth Battinelli, MD, PhD, and Jason Gotlib, MD, MS What are your goals for this year’s education program? Dr. Gotlib: We...

Scientific Program Preview

Interview with Scientific Program Co-Chairs Robert Flaumenhaft, MD, PhD, and Charles Mullighan, MBBS (Hons), MD What are your goals for this year’s scientific program? Dr. Flaumenhaft:...

A Global Perspective on Chronic Myeloid Leukemia

In the U.S. and other high-income countries, access to testing and first-, second-, and third-generation tyrosine kinase inhibitors has improved the management and prognosis...

Drug Problems: Hematologic Complications of Illicit Drug Use

In an Education Spotlight Session at this year’s ASH Annual Meeting, experts will be looking at the potentially devastating hematologic complications of illicit drug...
On location

Venetoclax Plus R-CHOP Improves Outcomes in BCL2-Positive DLBCL

For the substantial portion of patients with diffuse large B-cell lymphoma (DLBCL) with overexpression of the BCL2 protein, combining the BCL2 inhibitor venetoclax with...
On location

Rituximab-Lenalidomide Combo Superior to Rituximab Alone in Relapsed/Refractory Indolent NHL

For patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL), adding lenalidomide to rituximab treatment improved response rates and prolonged time to next treatment, compared with...
Advertisement

Current Issue

November 2019 Bonus ASH Annual Meeting Preview Edition (Volume 5, Issue...

This issue offers an inside look at this year’s annual meeting, advice for giving effective presentations, and more.